The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...
TipRanks on MSN1mon
IceCure Medical Awaits FDA Decision as ProSense® Gains AttentionIcecure Medical ( (ICCM)) has issued an update. IceCure Medical participated in the 2025 Society of Interventional Oncology ...
IceCure Medical (ICCM) announced it is in continued discussions with the U.S. FDA regarding its De Novo marketing authorization request for ...
Six studies of ProSense® in breast cancer were accepted as peer-reviewed abstracts, presented as e-posters during the conference, and are being published in the scientific journal, The Breast ...
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg View original content:https://www.prnewswire.com/news-releases/icecure-medical-reports-2024 ...
Q4 2024 Earnings Call Transcript March 27, 2025 IceCure Medical Ltd misses on earnings expectations. Reported EPS is $-0.08 ...
"Given the novelty of our product and the importance of breast cancer in public health, the FDA has included many stakeholders in the discussion of the De Novo marketing clearance for ProSense ...
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 ...
PR Newswire CAESAREA, Israel IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel /PRNewswire/ -- IceCure Medi ...
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback